{"id":"8bf2405d3189","type":"article","url":"https://hartvaat.nl/2025/01/01/serum-transthyretine-voor-en-na-tafamidisstart-als-uitkomstvoorspeller-bij-attr-/","title":"Serum-transthyretine vóór en na tafamidisstart als uitkomstvoorspeller bij ATTR-cardiomyopathie","title_en":"Serum Transthyretin Before and After Starting Tafamidis as Outcome Predictors in ATTR Cardiomyopathy","category":"hartfalen","category_label":"Hartfalen","professions":["apotheker","cardioloog"],"tags":["cardiale-amyloidose","cardiomyopathie-gerichte-therapie","laminopathie"],"journal":"JACC","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000690?dgcid=rss_sd_all","source_url":"https://doi.org/https://www.sciencedirect.com/science/article/pii/S0735109726000690?dgcid=rss_sd_all","authors":["Vincenzo Castiglione","Alberto Aimo","Maria Franzini","Angela Castiglione","Gianpaolo Palmieri","Olena Chubuchna","Veronica Musetti","Concetta Prontera","Silvia Masotti","Alberto Cipriani"],"significance":7,"published":"2026-03-01","source_date":"2025-01-01","image":"","kennis":[],"congress":"","summary_en":"This study examined the prognostic value of serum transthyretin levels before and after tafamidis initiation in patients with ATTR cardiomyopathy, exploring whether transthyretin dynamics can guide treatment monitoring.","created":"2026-07-03T10:25:46Z","updated":"2026-07-03T13:25:08Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Onderzoek naar de prognostische waarde van serum-transthyretineniveaus vóór en na het starten van tafamidis bij patiënten met transthyretine-amyloïd cardiomyopathie.","abstract_original":"Publication date: Available online 18 February 2026Source: JACC"}